Breast Cancer Research and Treatment

, Volume 171, Issue 1, pp 243–244 | Cite as

Tamoxifen-induced fatty liver disease in a Caucasian patient

  • Karel EechouteEmail author
  • Ron H. J. Mathijssen
  • Teun van Gelder
Letter to the Editor


Tamoxifen is a well-established hormonal treatment modality for hormone receptor-positive breast cancer. Though generally well tolerated, typical side effects resulting from its selective hormonal receptor modulation, such as hot flushes, are frequently reported. Although preclinical data indicate that tamoxifen also induces lipid accumulation in the liver, up until now hepatic steatosis has not been reported in Caucasian patients [1]. This is in contrast with patients of Asian ethnicity, in whom tamoxifen-induced hepatic steatosis has been described in more than 40% of the cases [2].

Case presentation

We observed a 52-year-old female patient who had been diagnosed with locoregional hormone receptor-positive breast cancer in September 2015. She underwent a mastectomy with a sentinel node procedure and subsequently received adjuvant chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel). In March 2016, after completing a complete course of chemotherapy,...


Compliance with ethical standards

Conflict of interest

Karel Eechoute declares that he has no conflict of interest. Ron Mathijssen declares that he has no conflict of interest. Teun van Gelder declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Saito K, Goda K, Kobayashi A, Yamada N, Maekawa K, Saito Y, Sugai S (2017) Arachidonic acid-containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen-induced hepatic phospholipidosis. J Appl Toxicol 37:943–953CrossRefPubMedGoogle Scholar
  2. 2.
    Lin Y, Liu J, Zhang X, Li L, Hu R, Liu J, Deng Y, Chen D, Zhao Y, Sun S et al (2014) A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. Cancer Sci 105:1182–1188CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Erasmus Medical CenterRotterdamThe Netherlands

Personalised recommendations